Table 1 Baseline characteristics of the patients (n = 216)

Gender (Male/Female), n (%)

180 (83)/36 (17)

Alcohol/HCV/other etiologies, n (%)

97 (45)/ 78 (36)/ 41 (19)

Prior radiological ascites (no / yes), n (%)

198 (92) / 18 (8)

Diuretic treatment (no/yes, not available), n (%)

133 (62)/67 (31)/16 (7)

Esophageal varices (yes/no/not available), n (%)

72 (33)/131 (61)/13 (6)

Child-Pugh (A5/A6/B/ not available), n (%)

139 (64)/39 (19)/18 (7.4)/20 (9.6)

BCLC-B (0/A/B), n (%)

10 (5)/77 (37)/129 (58)

Bilirubin (mg/dL), median (range), IQR

1 (0.2–5.4), 0.93–1.33

Albumin, (g/L), median (range), IQR

40 (27–49), 36–43

AFP (ng/mL), median (range), IQR

12.8 (0.3–13-000), 4.9–60.3

Cr (mg/dL), median (range), IQR

0.84 (0.43–3.96), 0.72–0.99

Sodium (mEq/L), median (range), IQR

141 (130–146), 138–142

AST (IU/L), median (range), IQR

50 (15–285), 32–84

ALT (IU/L), median (range), IQR

38 (7–278), 25–76.5

GGT (IU/L), median (range), IQR

120 (16–2011), 67–212

AP (IU/L), median (range), IQR

108 (36–370), 86.5–138.5

PT (%), median (range), IQR

84 (36–118), 75–94

Platelets (× 10⁹/L), median (range), IQR

113 (22–460), 79–159

Hemoglobin (g/dL), median (range), IQR

13.6 (7.6–17.9), 12.4–14.9

Clinically Significant Portal Hypertension (yes/no), n

157 (73) / 59 (27)

Main nodule diameter (mm), median (range), IQR

35 (11–100), 23–48

Previous treatment (ablation/resection), n (%)

44 /8

ALBI 1/2/3/not available, n

81 /96/1/38

Beads size 300–500 μm/ 100–300 μm, n

135/81

Use of Cone Beam CT (no/yes), n

187/29

Dose of doxorubicin (mg), median (range), IQR

90 (7.5–150), 70–140